Isracann Biosciences Inc. - CEO, Phil Floucault
CEO, Phil Floucault
Source: Cowichan Valley Citizen
  • Isracann Bioscience (IPOT) announces that its first shipment of cannabis strains has cleared Israeli customs
  • The three strains shipped are called: Liberty Haze, Hell Monkey, and Grape Stomper
  • Canadian quality cannabis will soon be grown in Israel and available to Israeli customers
  • Isracann engages in the cultivation, manufacturing, distribution, and branding of medical cannabis-based products
  • Isracann Biosciences Inc. (IPOT) opened trading at C$0.045

Isracann Bioscience (IPOT) announces that its first shipment of cannabis strains has cleared Israeli customs and are being raised as mother stock.

“The Israeli market will now have access to premium Canadian high THC genetics,” notes CEO Phil Floucault.

“The three strains we shipped are called: Liberty Haze, Hell Monkey, and Grape Stomper. All three strains have received a positive response from consumers in Canada, and I am looking forward to being able to make them available to the Israeli market.”

The three strains sent were developed as part of United Greeneries’ “Grass Roots” genetics program, which aims to produce novel high THC strains with commercially high yields.

Currently being sold as premium cannabis flower in Canada, the three strains represent some of the top performing genetics in United Greeneries’ catalogue. With the support of United Greeneries and Isracann, all three strains have been integrated into the Intelicanna facility and are being prepared as the initial Israeli mother stock.

Phil Floucault continues, “The planning and preparation by the teams in Canada and Israel made this genetics shipment happen smoothly. The growing teams are now fully engaged and working to expedite the process of scaling to full production. In the near term, Canadian quality cannabis will be grown in Israel and available to Israeli customers. Canadian genetics, Israeli grown.”

Isracann engages in the cultivation, manufacturing, distribution, and branding of medical cannabis-based products.

Isracann Biosciences Inc. (IPOT) opened trading at C$0.045.


More From The Market Online

The Market Online’s Weekly Cannabis Report – June 21, 2024

A Canadian cannabis pharmaceutical stock, has signed a licensing agreement with Remidose Aerosols to acquire its metered dose inhaler.

MediPharm bolsters revenue with new medical cannabis products

MediPharm Labs (TSX:LABS), a cannabis pharmaceutical stock, increases revenue through a new licensing agreement with Remidose Aerosols.

Justera Health to acquire cannabis brand Port North Extracts

Justera Health (CSE:VTAL) reveals it will acquire 100 per cent of the issued and outstanding shares of Port North Extracts.

The Market Online’s Weekly Cannabis Report – June 14, 2024

A top Mexican cannabis and CBD company revealed it has executed the first purchase order of products from Restorative Botanicals in the U.S.